Analysts say they expect the biotech's HIV treatment pipeline to lead the way for 2006 revenue, in part because Gilead Sciences received approval in 2006 for its combination drug Atripla. The drug combines Gilead's Truvada with Bristol-Myers Squibb's Sustiva to create the first once-a-day HIV treatment, and one analyst says he anticipates a rapid increase in sales of Atripla.

Related Summaries